Ovarian Clear Cell Carcinoma: An Endometriosis-Associated Cancer with Therapeutic Challenges

Ruby Yun‐Ju Huang, Jimmy Jin-Che Lin
Cold Spring Harbor perspectives in medicine · 2024 · vol. 15(8) , pp. a041315 · doi:10.1101/cshperspect.a041315 · PMID:39284670 · W4402582266
article OA: green CC0
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Ovarian clear cell carcinoma, linked to endometriosis, exhibits therapeutic resistance and poor prognosis, necessitating multidimensional analyses of tumor heterogeneity for improved patient stratification and novel treatment development.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This paper reviews ovarian clear cell carcinoma (OCCC), focusing on how it differs from other epithelial ovarian cancer subtypes in pathology, molecular profiles, and biology, and why it poses major therapeutic challenges. It notes that OCCC has higher incidence in East Asia, is associated with endometriosis, shows relative resistance to conventional treatment regimens, and has the worst stage-adjusted prognosis among ovarian cancer subtypes, emphasizing the need for better patient stratification. The paper proposes that stratification could be improved through comprehensive multidimensional analyses of tumor heterogeneity, including intertumor variation assessed via genomic, epigenomic, and transcriptomic profiling. It does not present new experimental data and provides an integrative perspective rather than a specific study outcome. This paper is centrally about endometriosis-associated cancer — it explicitly frames OCCC as an endometriosis-associated cancer and discusses therapeutic challenges in that context.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer with distinct pathological features, molecular profiles, and biological functions. OCCC has high incidence rates in East Asia compared to the Western hemisphere and Europe and is associated with endometriosis. With its relative resistance to conventional treatment regimens and the worst stage-adjusted prognosis among ovarian cancer subtypes, there is an urgent need to optimize therapeutic options and to improve patient outcomes. To achieve this goal, better patient stratification strategies are required. These strategies could derive from comprehensive and in-depth multidimensional analysis of tumor heterogeneity. Understanding intertumor heterogeneity could assist us in stratifying OCCC patients based on features that are prognostic or predictive. Recent genomic, epigenomic, and transcriptomic profiling analyses allow us to provide an integrative perspective on the diverse heterogeneity in OCCC that could pave the way for novel translational research and clinical development in the future.
Full text 1,712 characters · extracted from oa-doi-fallback · click to expand
Ovarian Clear Cell Carcinoma: An Endometriosis-Associated Cancer with Therapeutic Challenges - 1School of Medicine, College of Medicine, National Taiwan University, Taipei 10051, Taiwan - 2Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan - 3Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore - 4Master's Program in Smart Medicine and Health Informatics, International College, National Taiwan University, Taipei 10051, Taiwan - Correspondence: rubyhuang{at}ntu.edu.tw Abstract Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer with distinct pathological features, molecular profiles, and biological functions. OCCC has high incidence rates in East Asia compared to the Western hemisphere and Europe and is associated with endometriosis. With its relative resistance to conventional treatment regimens and the worst stage-adjusted prognosis among ovarian cancer subtypes, there is an urgent need to optimize therapeutic options and to improve patient outcomes. To achieve this goal, better patient stratification strategies are required. These strategies could derive from comprehensive and in-depth multidimensional analysis of tumor heterogeneity. Understanding intertumor heterogeneity could assist us in stratifying OCCC patients based on features that are prognostic or predictive. Recent genomic, epigenomic, and transcriptomic profiling analyses allow us to provide an integrative perspective on the diverse heterogeneity in OCCC that could pave the way for novel translational research and clinical development in the future.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (68)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pmc
last seen: 2026-05-17T02:30:03.883495+00:00
pubmed
last seen: 2026-05-29T00:32:17.006914+00:00
License: CC0 · commercial use OK